-
Electronic (PDF)
-
Site License
-
Enterprisewide
BioTime, Inc. (BTX) - Financial and Strategic SWOT Analysis Review
GlobalData, August 2011, Pages: 48
BioTime, Inc. (BTX) - Financial and Strategic SWOT Analysis Review
Summary
BioTime, Inc. (BioTime) is a biomedical company. It is engaged in the research, development and manufacture of medical devices for in-vitro diagnostic markets. The company is involved in two areas of biomedical research and product development. It operates in two business segments, namely, plasma volume expanders products and regenerative medicine. Regenerative medicine is the therapies based on human embryonic stem cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. The company's lead blood plasma expander product, Hextend, is used in the treatment of hypovolemia. The company principally operates in the US and Asia. BioTime is headquartered in California, the US.
BioTime, Inc. Key Recent Developments…
Jul 19, 2011 BioTime Announces Issuance Of Second US Glycosan Hydrogel Patent
Jul 15, 2011 BioTime Receives $335,900 SBIR Grant
Jun 29, 2011 BioTime Appoints William Tew As Chief Commercial Officer
Jun 09, 2011 BioTime Reports First Complete Sequencing Of Nuclear Genome Of Five GMP-Compliant Human Embryonic Stem Cell Lines At Jefferies 2011 Global Healthcare Conference
Jun 03, 2011 BioTime Receives NIH Approval For Two GMP Human Embryonic Stem Cell Lines
This comprehensive SWOT profile of BioTime, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
List of Tables
List of Figures
Section 1 - About the Company
BioTime, Inc. - Key Facts
BioTime, Inc. - Key Employees
BioTime, Inc. - Key Employee Biographies
BioTime, Inc. - Major Products and Services
BioTime, Inc. Pipeline Products by Development Stage
BioTime, Inc. - Pharmaceutical Pipeline Products Data
BioTime, Inc., Pipeline Products by Therapy Area
BioTime, Inc., Pipeline Products by Development Phase
BioTime, Inc. - History
BioTime, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
BioTime, Inc. - Business Description
BioTime, Inc. - Corporate Strategy
BioTime, Inc. - SWOT Analysis
SWOT Analysis - Overview
BioTime, Inc. - Strengths
Strength - Key Technology Platforms
Strength - Intellectual Property
Strength - Lead Product: Hextend
Strength - Improving Liquidity Reserves
Strength - Increased Asset Position
BioTime, Inc. - Weaknesses
Weakness - Overdependence on the US Market
Weakness - Equity Financing
Weakness - Declining Operational Efficiency
BioTime, Inc. - Opportunities
Opportunity - Regenerative Medicine Market
Opportunity - Acquisition of ES Cell International Pte Ltd
Opportunity - Formation of New Subsidiary
Opportunity - New Product Launches
BioTime, Inc. - Threats
Threat - Introduction of Innovative Technologies
Threat - Competitive Landscape
Threat - Stringent Government Regulations
BioTime, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
BioTime, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
BioTime, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
BioTime, Inc., Medical Equipment, Deals By Year, 2005 to YTD 2011
BioTime, Inc., Medical Equipment, Deals By Type, 2005 to YTD 2011
BioTime, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
Jul 19, 2011: BioTime Announces Issuance Of Second US Glycosan Hydrogel Patent
Jul 15, 2011: BioTime Receives $335,900 SBIR Grant
Jun 29, 2011: BioTime Appoints William Tew As Chief Commercial Officer
Jun 09, 2011: BioTime Reports First Complete Sequencing Of Nuclear Genome Of Five GMP-Compliant Human Embryonic Stem Cell Lines At Jefferies 2011 Global Healthcare Conference
Jun 03, 2011: BioTime Receives NIH Approval For Two GMP Human Embryonic Stem Cell Lines
May 10, 2011: BioTime Announces Issuance Of US Glycosan Hydrogel Patent
May 05, 2011: BioTime Reports Net Loss Of $3.4m For Q1 2011
Apr 12, 2011: BioTime Presents Data At FABS 2011 On Restoration Of Cell Lifespan Using iPS Cell Technology
Mar 15, 2011: BioTime Reports Net Loss Of $3m For Q4 2010
Jan 10, 2011: BioTime To Present Preclinical Data On OTX-CP03 And OTX-CP07 At STEM 2011 In Gurgaon, India
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Geron Corporation
Hospira, Inc.
Baxter International Inc.
B. Braun Melsungen AG
Sanofi
Alpha Therapeutic Corporation
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW6
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
